External-beam radiotherapy for localized extrahepatic cholangiocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 3, 2006, Pages 772-779

  Ben David, Merav A ^a,b   Griffith, Kent A ^b,c   Abu Isa, Eyad ^b   Lawrence, Theodore S ^a,b   Knol, James ^b   Zalupski, Mark ^b   Ben Josef, Edgar ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Extrahepatic cholangiocarcinoma; Gallbladder carcinoma; Hilar carcinoma; Radiation therapy

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DISEASES; MEDICAL PROBLEMS; PATIENT MONITORING; SURGERY;

EXTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; HILAR CARCINOMA; MACROSCOPIC RESIDUAL DISEASE;

RADIOTHERAPY;

BROXURIDINE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHOLANGITIS; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; EXTRAHEPATIC CHOLANGIOCARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INDUCED EMESIS; SURVIVAL TIME; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 33748924469     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.061     Document Type: Article

References (48)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Sakamoto E., Nimura Y., Hayakawa N., et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: A histologic analysis of 62 resected cases. Ann Surg 227 (1998) 405-411
3. Burke E.C., Jarnagin W.R., Hochwald S.N., et al. Hilar cholangiocarcinoma: Patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228 (1998) 385-394
4. Bartlett D.L. Gallbladder cancer. Semin Surg Oncol 19 (2000) 145-155
5. Khan S.A., Davidson B.R., Goldin R., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 51 Suppl. 6 (2002) VI1-VI9
6. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224 (1996) 463-475
7. Cubertafond P., Mathonnet M., Gainant A., et al. Radical surgery for gallbladder cancer. Results of the French Surgical Association Survey. Hepatogastroenterology 46 (1999) 1567-1571
8. Wilkinson D.S. Carcinoma of the gall-bladder: an experience and review of the literature. Aust N Z J Surg 65 (1995) 724-727
9. Carriaga M.T., and Henson D.E. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 75 1 Suppl (1995) 171-190
10. Olnes M.J., and Erlich R. A review and update on cholangiocarcinoma. Oncology 66 (2004) 167-179
11. Jarnagin W.R. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 19 (2000) 156-176
12. Kosuge T., Yamamoto J., Shimada K., et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 230 (1999) 663-671
13. Klempnauer J., Ridder G.J., Werner M., et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma?. Cancer 79 (1997) 26-34
14. Nimura Y. Extended surgery in bilio-pancreatic cancer: The Japanese experience. Semin Oncol 29 Suppl. 20 (2002) 17-22
15. Hejna M., Pruckmayer M., and Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34 (1998) 977-986
16. Malik I.A., Aziz Z., Zaidi S.H., et al. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 26 (2003) 174-177
17. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 (2004) 578-586
18. Gerhards M.F., van Gulik T.M., Gonzalez Gonzalez D., et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27 (2003) 173-179
19. Foo M.L., Gunderson L.L., Bender C.E., et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 39 (1997) 929-935
20. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221 (1995) 788-797 discussion 797-798
21. Houry S., Haccart V., Huguier M., et al. Gallbladder cancer: Role of radiation therapy. Hepatogastroenterology 46 (1999) 1578-1584
22. Kresl J.J., Schild S.E., Henning G.T., et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 52 (2002) 167-175
23. Gonzalez Gonzalez D., Gerard J.P., Maners A.W., et al. Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 10 (1990) 131-141
24. Treadwell T.A., and Hardin W.J. Primary carcinoma of the gallbladder. The role of adjunctive therapy in its treatment. Am J Surg 132 (1976) 703-706
25. Fleming I.D., Cooper J.S., et al. HD. AJCC cancer staging manual. 5th ed. (1998), Lippincott-Raven Publishers, Philadelphia
26. Cancer Therapy Evaluation Program (2003). http://ctep.cancer.gov/forms/CTCAEv3.pdf Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. December 12, Available online at http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed June 30, 2006.
27. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
28. Robertson J.M., McGinn C.J., Walker S., et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 39 (1997) 1087-1092
29. Robertson J.M., Lawrence T.S., Andrews J.C., et al. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 37 (1997) 325-330
30. Robertson J.M., Lawrence T.S., Dworzanin L.M., et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 11 (1993) 1286-1293
31. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
32. Lillemoe K.D., and Cameron J.L. Surgery for hilar cholangiocarcinoma: The Johns Hopkins approach. J Hepatobiliary Pancreat Surg 7 (2000) 115-121
33. Nakeeb A., Tran K.Q., Black M.J., et al. Improved survival in resected biliary malignancies. Surgery 132 (2002) 555-564
34. Wakai T., Shirai Y., Moroda T., et al. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 103 (2005) 1210-1216
35. Benassai G., Mastrorilli M., Quarto G., et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 73 (2000) 212-218
36. Takai S., Satoi S., Toyokawa H., et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: A retrospective, single-institution experience. Pancreas 26 (2003) 243-249
37. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
38. Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 98 (2003) 1689-1700
39. Todoroki T., Ohara K., Kawamoto T., et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 581-587
40. Sagawa N., Kondo S., Morikawa T., et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 35 (2005) 548-552
41. Chao T.C., and Greager J.A. Primary carcinoma of the gallbladder. J Surg Oncol 46 (1991) 215-221
42. Henson D.E., Albores-Saavedra J., and Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70 (1992) 1493-1497
43. Henson D.E., Albores-Saavedra J., and Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 70 (1992) 1498-1501
44. Fritz P., Brambs H.J., Schraube P., et al. Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas. Int J Radiat Oncol Biol Phys 29 (1994) 855-861
45. Mittal B., Deutsch M., and Iwatsuki S. Primary cancers of extrahepatic biliary passages. Int J Radiat Oncol Biol Phys 11 (1985) 849-854
46. Flickinger J.C., Epstein A.H., Iwatsuki S., et al. Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 68 (1991) 289-294
47. Kopelson G., Harisiadis L., Tretter P., et al. The role of radiation therapy in cancer of the extra-hepatic biliary system: An analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2 (1977) 883-894
48. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53 (2002) 810-821